X4 Pharmaceuticals, Inc. (XFOR) Q1 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

first quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Dan Ferry from LifeSci Advisors. Thank you, Mr. Ferry. You may begin. Thank you, Operator, and good morning, everyone. Thank you for joining us today. Presenting on today's call will be Dr. Paula Regan, X4's President and CEO, and the company's Chief Financial Officer, Adam Mostafa. Following prepared remarks, we will open up the call to your questions and will be joined by Chief Commercial Officer, Mark Baldry, Chief Medical Officer, Dr. Christoph Arbett-Engels, Chief Operating Officer, Dr. Mary Bibiasi, Chief Scientific Officer, Dr. Art Tavares, and Jose Juves, Head of Corporate and Patient Affairs. As a reminder, on today's call, the company will be making forward-looking statements regarding regulatory and product development and commercialization plans, as well as research activities. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in X4's most recent filings with the SEC, including this year's Form 10-K, which was filed on March 21, 2024, and in the company's Form 10-Q, which is expected to be filed later today. I'll now turn it over to Paula Regan. Paula? Thanks so much, Dan, and welcome, everyone. Following last week's approval of Zol Remdy, it's exciting to reiterate today why this critical regulatory achievement represents a significant opportunity to improve the lives of WHIM patients and offers a strong platform for the company's growth. More specifically, I'll touch on our plans...